Literature DB >> 11282191

Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy.

A Faustini1, E Franco, M Sangalli, T Spadea, R M Calabrese, M Cauletti, C A Perucci.   

Abstract

A population survey was conducted to assess the duration of anti-HBs levels > 10 IU/l in vaccinees living in Lazio Region (Italy) 5 years after the introduction (15 June 1991) of compulsory vaccination of new-borns and 11-year-old children. A random sample of 1192 (533 children born in 1991--92 and 659 adolescents born in 1979--81) was selected. In 92.9% of children and 94.1% of adolescents anti-HBs titres were protective (> or = 10 IU/l). These subjects with protective titres were divided into three categories: low responders (anti-HBs titres = 10--500 IU/l), medium responders (anti-HBs titres = 501--2000 IU/l) and high responders (anti-HBs titres > 2000 IU/l). Factors associated with the level of response were analysed, using a multiple politomic logistic regression analysis. Greater age at first dose (11--12 years) was associated with higher titres (OR = 2.1, 95% CI = 1.4--3.2 for medium responders and OR = 3.0, 95% CI = 1.9--4.8 for high responders). Simultaneous administration of DT vaccine was associated with lower titres (OR = 0.4, 95% CI = 0.2-0.8 for medium responders and OR = 0.3, 95% CI = 0.1--0.7 for high responders).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282191     DOI: 10.1016/s0264-410x(01)00005-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Long-term immune protection against HBV: associated factors and determinants.

Authors:  Marianna Mastrodomenico; Mario Muselli; Luca Provvidenti; Maria Scatigna; Serena Bianchi; Leila Fabiani
Journal:  Hum Vaccin Immunother       Date:  2021-01-31       Impact factor: 3.452

3.  Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study.

Authors:  Pierre Van Damme; Anna Moiseeva; Igor Marichev; Anne-Diane Kervyn; Robert Booy; Sherine Kuriyakose; Andrew Brockway; Su-Peing Ng; Maarten Leyssen; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-12-20       Impact factor: 3.090

4.  Should a booster dose be administered in children after mass immunization for hepatitis B?

Authors:  Selma Tosun; Serol Deveci; Yunus Kaplan; Erhun Kasirga
Journal:  Hepat Mon       Date:  2011-06       Impact factor: 0.660

5.  The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy.

Authors:  Nicola Coppola; Anna Rita Corvino; Stefania De Pascalis; Giuseppe Signoriello; Eliana Di Fiore; Albert Nienhaus; Evangelista Sagnelli; Monica Lamberti
Journal:  BMC Infect Dis       Date:  2015-03-25       Impact factor: 3.090

6.  Persistence of Immunity for Hepatitis B Virus among Heathcare Workers and Italian Medical Students 20 Years after Vaccination.

Authors:  Luca Coppeta; Andrea Pompei; Ottavia Balbi; Ludovico M De Zordo; Federica Mormone; Sara Policardo; Piergiorgio Lieto; Antonio Pietroiusti; Andrea Magrini
Journal:  Int J Environ Res Public Health       Date:  2019-04-29       Impact factor: 3.390

7.  Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia.

Authors:  Asgeir Johannessen; Bitsatab Mekasha; Hailemichael Desalegn; Hanna Aberra; Kathrine Stene-Johansen; Nega Berhe
Journal:  Vaccines (Basel)       Date:  2021-04-26

Review 8.  Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis: an update.

Authors:  Raymond S Koff
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.